Next Gen Diagnostics, a global American leader in the development of validated machine learning models for the detection of transmission based on the whole genome sequence (WGS) and for the determination of bacterial susceptibility to antibiotics, has announced an agreement for the sequencing and analysis of a unique collection of highly resistant bacterial infections with the Sheba Medical Center, Israel's largest medical complex in the Middle East.
"NGD is committed to providing Israel with its systems for detecting infection transmission and predicting resistance to WGS-based medicines. Recent work has shown . . .
🔒 Cet article est réservé aux abonnés. Inscrivez-vous pour lire la suite !
